Completed PHASE2 INTERVENTIONAL 1-arm NCT00964171

Efavirenz as Second-Line Therapy in Treating Patients With Metastatic Pancreatic Cancer (PANTER)

A Phase II Trial to Assess the Efficacy of Efavirenz as Second-line Monotherapy for the Treatment of Advanced Pancreatic Adenocarcinomas.

Sponsor: Institut Bergonié

Conditions Pancreatic Cancer

Interventions Efavirenz 600mg

Updated 6 times since 2017 Last updated: Aug 11, 2025 Started: Aug 31, 2008 Primary completion: Jul 31, 2010 Completion: Jul 31, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Pancreatic Cancer, this trial is completed. The trial is conducted by Institut Bergonié and has accumulated 6 data snapshots since 2008. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2

Status: Unknown → Completed
Sep 2024 — Sep 2025 [monthly]

Unknown PHASE2
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE2

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE2
Jun 2018 — Jan 2021 [monthly]

Unknown Status PHASE2

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Unknown Status PHASE2

First recorded

Aug 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Institut Bergonié

Data source: Institut Bergonié

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Bordeaux, France